After 16 Years, Roche's Pharma Division Head Decides To Step Down - Roche Holding (OTC:RHHBF), Roche Holding (OTC:RHHVF), Roche Holding (OTC:RHHBY)

Roche Holdings AG's RHHBY head of its pharmaceuticals division, Bill Anderson, has decided to leave after 16 years with the company.
Bill Anderson would quit at the end of the year "to pursue opportunities outside of Roche," with a successor due to be named by March 2023, Roche said in a statement.
Thomas Schinecker will become the ad interim CEO of Roche Pharmaceuticals starting 1 January 2023, when he hands over the CEO Roche Diagnostics role to Matt Sause as previously announced.
Also see: Roche's Another Alzheimer's Hopeful Flops In Phase 3 Program, Second Trial Setback Within Months.
As previously announced in July 2022, Christoph Franz has decided not to seek re-election as Chairman.
The Board of Directors will propose Severin Schwan as the new Chairman and has appointed Thomas Schinecker as the new Roche Group CEO, effective 14 March 2023.
The company added that Nestle NSRGY CEO Mark Schneider and Akiko Iwasaki, an Immunobiology professor at Yale University, would stand for election as new board members at next year's annual general meeting.